Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma
(2002) In Journal of Clinical Oncology 20(22). p.4413-4419- Abstract
- Purpose: This trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group compares the use of high-dose therapy (HDT) as part of primary treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide followed by involved-field (IF) radiotherapy in a randomized, multicenter, phase III study. Patients and Methods: Three hundred twelve patients with "aggressive" non-Hodgkin's lymphoma aged greater than or equal to 60 years with elevated serum lactate dehydrogenase levels were included from 1990 to 1997. Patients with at least a minor response after two cycles of CHOEP (CHOP + etoposide 3 x 100 mg/m(2)) were to receive three further cycles of CHOEP followed by IF radiotherapy (arm A) or one further cycle... (More)
- Purpose: This trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group compares the use of high-dose therapy (HDT) as part of primary treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide followed by involved-field (IF) radiotherapy in a randomized, multicenter, phase III study. Patients and Methods: Three hundred twelve patients with "aggressive" non-Hodgkin's lymphoma aged greater than or equal to 60 years with elevated serum lactate dehydrogenase levels were included from 1990 to 1997. Patients with at least a minor response after two cycles of CHOEP (CHOP + etoposide 3 x 100 mg/m(2)) were to receive three further cycles of CHOEP followed by IF radiotherapy (arm A) or one further cycle of CHOEP followed by autologous stem-cell transplantation and IF radiotherapy (arm B). Results: Among 158 patients randomized to arm B, 103 (65%) received HDT. The complete remission rate at the end of treatment was 62.9% in arm A and 69.9% in arm B. With a median observation time of 45.5 months, overall survival for all 312 patients was 63% after 3 years (63% for arm A, 62% for arm B; P = .68). Event-free survival was 49% for arm A versus 59% for arm B (P = .22). Relapse in arm B was associated with a significantly worse survival rate than relapse in arm A (P < .05). Relapse after HDT occurred early (median interval, 3 months). Six patients developed secondary neoplasia, three in arm A and three in arm B. Conclusion: Results of the randomized trial comparing CHOP-like chemotherapy with early HDT do not support the use of HDT with carmustine, etoposide, cytarabine, and melphalan following shortened standard chemotherapy. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/323452
- author
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Oncology
- volume
- 20
- issue
- 22
- pages
- 4413 - 4419
- publisher
- American Society of Clinical Oncology
- external identifiers
-
- pmid:12431962
- wos:000179267200002
- scopus:0037111830
- ISSN
- 1527-7755
- DOI
- 10.1200/JCO.2002.07.075
- language
- English
- LU publication?
- no
- id
- c3ac9f80-11f8-4d66-9522-8c076ab60131 (old id 323452)
- date added to LUP
- 2016-04-01 12:22:55
- date last changed
- 2022-03-13 17:11:15
@article{c3ac9f80-11f8-4d66-9522-8c076ab60131,
abstract = {{Purpose: This trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group compares the use of high-dose therapy (HDT) as part of primary treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide followed by involved-field (IF) radiotherapy in a randomized, multicenter, phase III study. Patients and Methods: Three hundred twelve patients with "aggressive" non-Hodgkin's lymphoma aged greater than or equal to 60 years with elevated serum lactate dehydrogenase levels were included from 1990 to 1997. Patients with at least a minor response after two cycles of CHOEP (CHOP + etoposide 3 x 100 mg/m(2)) were to receive three further cycles of CHOEP followed by IF radiotherapy (arm A) or one further cycle of CHOEP followed by autologous stem-cell transplantation and IF radiotherapy (arm B). Results: Among 158 patients randomized to arm B, 103 (65%) received HDT. The complete remission rate at the end of treatment was 62.9% in arm A and 69.9% in arm B. With a median observation time of 45.5 months, overall survival for all 312 patients was 63% after 3 years (63% for arm A, 62% for arm B; P = .68). Event-free survival was 49% for arm A versus 59% for arm B (P = .22). Relapse in arm B was associated with a significantly worse survival rate than relapse in arm A (P < .05). Relapse after HDT occurred early (median interval, 3 months). Six patients developed secondary neoplasia, three in arm A and three in arm B. Conclusion: Results of the randomized trial comparing CHOP-like chemotherapy with early HDT do not support the use of HDT with carmustine, etoposide, cytarabine, and melphalan following shortened standard chemotherapy.}},
author = {{Kaiser, U and Uebelacker, L and Abel, U and Birkmann, J and Trumper, L and Schmalenberg, H and Karakas, T and Metzner, B and Hossfeld, DK and Bischoff, HG and Franke, A and Reiser, M and Muller, P and Mantovani, L and Grundeis, M and Rothmann, F and von Seydewitz, CU and Mesters, RM and Steinhauer, EU and Krahl, D and Schumacher, K and Kneba, M and Baudis, M and Schmitz, N and Pfab, R and Koppler, H and Parwaresch, R and Pfreundschuh, M and Havemann, K}},
issn = {{1527-7755}},
language = {{eng}},
number = {{22}},
pages = {{4413--4419}},
publisher = {{American Society of Clinical Oncology}},
series = {{Journal of Clinical Oncology}},
title = {{Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma}},
url = {{http://dx.doi.org/10.1200/JCO.2002.07.075}},
doi = {{10.1200/JCO.2002.07.075}},
volume = {{20}},
year = {{2002}},
}